Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 7.99M | 9.29M | 5.49M | 1.25M | 14.94M | 3.15M |
Gross Profit | -1.54M | 9.29M | -32.61M | -560.83K | 16.72M | -30.39M |
EBITDA | -37.27M | -37.53M | -46.05M | -50.49M | -45.44M | -43.99M |
Net Income | -40.58M | -40.67M | -50.73M | -52.80M | -44.16M | -44.78M |
Balance Sheet | ||||||
Total Assets | 22.25M | 32.19M | 61.53M | 91.28M | 83.40M | 99.53M |
Cash, Cash Equivalents and Short-Term Investments | 13.14M | 22.46M | 48.51M | 76.29M | 64.37M | 84.87M |
Total Debt | 7.13M | 8.88M | 14.70M | 19.32M | 10.05M | 7.15M |
Total Liabilities | 15.67M | 14.69M | 24.45M | 25.60M | 17.91M | 20.62M |
Stockholders Equity | 6.58M | 17.50M | 37.09M | 65.68M | 65.49M | 78.91M |
Cash Flow | ||||||
Free Cash Flow | -34.88M | -36.40M | -39.96M | -41.98M | -39.75M | -33.09M |
Operating Cash Flow | -34.72M | -36.33M | -39.96M | -41.81M | -38.84M | -32.49M |
Investing Cash Flow | -63.00K | 32.00K | 25.00M | -24.61M | 9.11M | 4.46M |
Financing Cash Flow | 6.89M | 10.24M | 11.86M | 53.66M | 19.23M | 58.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $393.86M | 5.04 | -58.97% | ― | 23.81% | 146.45% | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
50 Neutral | $52.38M | ― | -221.66% | ― | 13.83% | 37.66% | |
50 Neutral | $60.79M | ― | -119.22% | ― | ― | 25.51% | |
44 Neutral | $56.07M | ― | -1131.02% | ― | ― | 23.55% | |
41 Neutral | $35.67M | ― | -853.05% | ― | ― | 34.97% | |
38 Underperform | $64.46M | ― | -679.15% | ― | -56.88% | -57.57% |
On June 30, 2025, Cue Biopharma, Inc. and MIL 40G, LLC amended their License Agreement, resulting in a reduced monthly rental rate from $235,883.98 to $147,545.69, effective immediately, with a 4% increase scheduled for April 15, 2027. Additionally, the agreement’s term was extended to April 14, 2028, and Cue Biopharma received a partial rent credit for June 2025, potentially improving its financial standing and operational flexibility.
The most recent analyst rating on (CUE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.
On June 4, 2025, Cue Biopharma, Inc. appointed Jill Broadfoot to its board of directors, where she will serve as Chair of the Audit Committee. Additionally, the company’s stockholders approved the 2025 Stock Incentive Plan during the annual meeting. On the same day, Kerri-Ann Millar announced her resignation as Chief Financial Officer, effective June 13, 2025, with CEO Daniel R. Passeri stepping in as interim CFO. Furthermore, the company filed a Certificate of Amendment to increase its authorized shares of capital and common stock, reflecting strategic growth initiatives.
The most recent analyst rating on (CUE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.